Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 93 results:
Συντάκτης Τίτλος [ Τύπος(Asc)] Έτος
Φίλτρα: Συντάκτης is Anastasilakis, Athanasios D  [Clear All Filters]
Journal Article
Polyzos, S. A., Anastasilakis A. D., Iakovou I. P., & Partsalidou V. (2010).  Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man.. Arq Bras Endocrinol Metabol. 54(6), 578-82.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Yavropoulou M. P., & Makras P. (2021).  Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.. Maturitas. 147, 19-25.
Polyzos, S. A., & Anastasilakis A. D. (2016).  Periostin on the road to nonalcoholic fatty liver disease.. Endocrine. 51(1), 4-6.
Polyzos, S. A., Makras P., Anastasilakis A. D., Mintziori G., Kita M., Papatheodorou A., et al. (2017).  Periostin and sclerostin levels in juvenile Paget's disease.. Clin Cases Miner Bone Metab. 14(2), 269-271.
Makras, P., Polyzos S. A., Papatheodorou A., Kokkoris P., Chatzifotiadis D., & Anastasilakis A. D. (2013).  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.. Clin Endocrinol (Oxf). 79(4), 499-503.
Anastasilakis, A. D., Polyzos S. A., Makras P., Kampas L., Valeri R. Maria, Kyriakoulis D., et al. (2012).  Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature.. Hormones (Athens). 11(4), 419-27.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Paget's disease of bone: emphasis on treatment with zoledronic acid.. Expert Rev Endocrinol Metab. 4(5), 423-434.
Makedou, K., Kourtis A., Gkiomisi A., Toulis K. A., Mouzaki M., Anastasilakis A. D., et al. (2011).  Oxidized low-density lipoprotein and adiponectin levels in pregnancy.. Gynecol Endocrinol. 27(12), 1070-3.
Polyzos, S. A., Makras P., Tournis S., & Anastasilakis A. D. (2019).  Off-label uses of denosumab in metabolic bone diseases.. Bone. 129, 115048.
Gkastaris, K., Goulis D. G., Potoupnis M., Anastasilakis A. D., & Kapetanos G. (2020).  Obesity, osteoporosis and bone metabolism.. J Musculoskelet Neuronal Interact. 20(3), 372-381.
Anastasilakis, A. D., Savvides M., Polyzos S. A., Georgopoulos C., & Delaroudis S. (2010).  Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.. J Bone Miner Metab. 28(1), 108-10.
Polyzos, S. A., Anastasilakis A. D., Anagnostis P., Kita M., Arsos G., Moralidis E., et al. (2012).  Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.. Endokrynol Pol. 63(4), 312-5.
Perakakis, N., Polyzos S. A., Yazdani A., Sala-Vila A., Kountouras J., Anastasilakis A. D., et al. (2019).  Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study.. Metabolism. 154005.
Vachliotis, I. D., Anastasilakis A. D., Goulas A., Goulis D. G., & Polyzos S. A. (2022).  Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.. Diabetes Obes Metab. 24(9), 1702-1720.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Makras, P., Anastasilakis A. D., Polyzos S. A., Bisbinas I., Sakellariou G. T., & Papapoulos S. E. (2011).  No effect of rosuvastatin in the zoledronate-induced acute-phase response.. Calcif Tissue Int. 88(5), 402-8.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Ballaouri I., Efstathiadou Z., et al. (2009).  No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.. Clin Endocrinol (Oxf). 70(4), 522-6.
Anastasilakis, A. D., Tournis S., Yavropoulou M. P., Polyzos S. A., & Makras P. (2018).  Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcif Tissue Int. 103(1), 107-108.
Anastasilakis, A. D., Polyzos S. A., Tsoli M., Papatheodorou A., Kokkoris P., Kaltsas G., et al. (2017).  Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity.. Metabolism. 71, 198-201.
Anastasilakis, A. D., Toulis K. A., Polyzos S. A., Anastasilakis C. D., & Makras P. (2012).  Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.. Ther Clin Risk Manag. 8, 295-306.
Anastasilakis, A. D., Polyzos S. A., Vorkas P. A., Gkiomisi A., Yavropoulou M. P., Rauner M., et al. (2023).  Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study.. J Clin Med. 12(16), 
Makras, P., Polyzos S. A., & Anastasilakis A. D. (2016).  Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.. J Clin Endocrinol Metab. 101(9), L89-90.
Sakellariou, G. T., Sayegh F. E., Anastasilakis A. D., & Kapetanos G. A. (2013).  Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate.. Rheumatol Int. 33(11), 2917-20.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Geladari E. V., & Mantzoros C. S. (2014).  Irisin in patients with nonalcoholic fatty liver disease.. Metabolism. 63(2), 207-17.
Polyzos, S. A., Kountouras J., & Anastasilakis A. D. (2021).  Irisin in nonalcoholic fatty liver disease: Need for an updated meta-analysis.. Metabolism. 121, 154818.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.